+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Cardiac toxicity of combined vemurafenib and cobimetinib administration




Cardiac toxicity of combined vemurafenib and cobimetinib administration




International Journal of Clinical Pharmacology and Therapeutics 2019



Vemurafenib and cobimetinib are extremely effective in treating V600E-mutated metastatic melanoma, but their use is associated with toxic cardiac effects. Vemurafenib-induced prolonged QTc interval may be associated with ventricular fibrillation and sudden cardiac death. Cobimetinib-induced myocardial damage may lead to severely reduced heart function and lethal heart failure. Few data are available about the time course of recovery after these side effects. We provide the first description of cardiac recovery after potentially fatal cardiac side effects due to vemurafenib and cobimetinib administration. A 51-year-old woman was admitted to our hospital with diarrhea, vomiting, and asthenia. At admission, her left ventricular ejection fraction (LVEF) was severely reduced and QTc interval was extremely elongated (normal range QTc ≤ 440 ms). Blood levels of troponin I (normal values below 0.07 ng/mL) and brain natriuretic peptide (brain natriuretic peptide (BNP), normal range < 100 pg/mL) were elevated. During hospitalization, she developed recurrent runs of torsades de pointes degenerating into ventricular fibrillation, requiring direct current electric shock (DC shocks). Vemurafenib and cobimetinib were discontinued. Three weeks later, QTc was still higher than 500 ms and LVEF lower than 30%: an implantable cardioverter-defibrillator (ICD) was implanted. Myocardial function improved within 1 month, and QTc intervals became 500 ms 1 week later. After 6 months, a normal ejection fraction (> 55%) was observed, and the QTc interval was 455 ms. The patient died rather from metastatic melanoma recurrence 8 months later. This case report highlights the time-course of recovery after combined vemurafenib-cobimetinib-induced severe myocardial damage. Further research is warranted to assess whether and how antineoplastic therapy may be resumed after QT normalization and heart function recovery.
.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 066446650

Download citation: RISBibTeXText

PMID: 30704555


Related references

Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib. Pigment Cell and Melanoma Research 31(4): 516-522, 2017

Decreased photosensitivity to UVA on vemurafenib combined with cobimetinib. Journal of the European Academy of Dermatology and Venereology 2018, 2018

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. New England Journal of Medicine 371(20): 1867-1876, 2014

Recurrent Central Serous Chorioretinopathy Under Combined Vemurafenib and Cobimetinib Treatment. Klinische Monatsblatter für Augenheilkunde 233(4): 488-489, 2017

Vemurafenib and cobimetinib overcome resistance to vemurafenib in BRAF -mutant ganglioglioma. Neurology 91(11): 523-525, 2018

The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib. Oncotargets and Therapy 9: 3739-3752, 2016

Gene Expression Profiling in BRAF -Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. Clinical Cancer Research 23(17): 5238-5245, 2017

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet. Oncology 17(9): 1248-1260, 2017

Cobimetinib and vemurafenib for the treatment of melanoma. Expert Opinion on PharmacoTherapy 17(7): 1005-1011, 2016

Vemurafenib and cobimetinib in BRAF-mutated melanoma. Lancet. Oncology 15(12): E535, 2015

Cobimetinib/vemurafenib-associated bilateral serous retinopathy: a case report. Der Ophthalmologe 2018, 2018

Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Annals of Oncology 28(5): 1137-1144, 2017

Acute polyneuropathy in a metastatic melanoma patient treated with vemurafenib and cobimetinib. Neurology. Clinical Practice 7(5): 418-420, 2018

Vemurafenib plus cobimetinib in the treatment of mutated metastatic melanoma: the CoBRIM trial. Melanoma Management 2(3): 209-215, 2015

Posterior reversible encephalopathy syndrome due to combination of vemurafenib and cobimetinib for metastatic melanoma. Pigment Cell and Melanoma Research 30(2): 262-264, 2016